Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Sarcoma

Presenters

Na Zhu

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

N. Zhu1, Y. Hou1, Y. Ji1, Y. Qu2, Q. Cui2, C. Hui2

Author affiliations

  • 1 Pathology, Zhongshan Hospital, Fudan University, 201100 - Shanghai/CN
  • 2 Medicines, OrigiMed, 201100 - Shanghai/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3197

Background

Cardiac sarcoma is a rare tumor. Currently, there is a lack of data on the genomic profiling in Chinese cardiac sarcoma patients. In this study, we analyzed the genomic alterations and prognostic biomarkers of this kind of patients.

Methods

Total FFPE samples of 26 cardiac sarcoma patients who received operation during 2010 to 2018 were enrolled in this study. FFPE samples from these patients were collected for WES (Whole Exome Sequencing). Genomic alterations including single base substitution, copy number variations, gene fusions and rearrangement were assessed. Tumor mutational burden (TMB) was also analyzed by NGS algorithm.

Results

The cohort of 26 cardiac sarcoma patients included 13 males and 13 females with a median age of 54 (range 27-68). Patients were followed up for 8 years (10 patients) or until patients died (16 patients). The median overall survive (OS) was 14 months. This cohort included 18 angiosarcomas (AS), 6 intimal sarcomas (IS), 1 liposarcoma (LPS) and 1 synovial sarcoma (SS). The most commonly altered genes were KDR (35%), MDM2 (31%), FRS2 (27%), KMT2D (23%), CKD4 (23%), GLI1 (23%) and TERT (23%). Several druggable genomic alterations including amplification of CDK4 (6/26), KIT (5/26), KDR (2/26), PDGFRA (2/26), ERBB3 (1/26), and mutations of BRAF (1/26), BRCA1 (1/26) and PTEN (1/26) were found. AS patients with alterations of TP53, TRMT10C, ALMS1, CCDC157, CCNJL, KIAA2026 or OSBPL7 gene had a poor prognosis with a median OS of 3 months, while AS patients without alterations of any those genes had a median OS of 21 months. Interestingly, MDM2 amplification was only found in IS and LPS, but not in AS, which was confirmed by FISH analysis. The median TMB was 29 muts/Mb (2.3-56.5 muts/Mb) in this cohort.

Conclusions

Our study firstly revealed the genomic profiling of Chinese cardiac sarcoma patients. Several genes may be relevant with prognosis in AS, and MDM2 amplification may be a potential biomarker to distinguish between different subtypes. Most of the patients (92.3%) presented high TMB value which may potentially benefitted to immunotherapy. Due to limited number of patients, the correlation of gene mutations with clinical features need to be further analyzed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.